According to Zhituo Finance APP, on December 30, Saifen Technology (688758.SH) started its subscription, with an issue price of 4.32 yuan per share, a subscription limit of 0.008 million shares, a PE of 39.09 times, and belongs to the Star of the Shanghai Stock Exchange, with CITIC SEC as its exclusive sponsor.

The prospectus shows that Saifen Technology is committed to the research and production of liquid chromatography materials for drug analysis, testing, and separation purification, and is a high-tech enterprise integrating research, production, and global sales.

The company's core products are chromatography columns and chromatography media used for the analysis, testing, and separation purification of biopharmaceuticals and small molecule chemical drugs, spanning the entire process of drug development and production, applied in various stages including drug R&D, IND application, clinical trials, market application, and commercial production, being key core consumables needed by pharmaceutical companies, especially biopharmaceutical companies, from early drug R&D to large-scale commercial production.

For a long time, the global and China's chromatography market share has been mainly dominated by overseas manufacturers. In recent years, the country's high emphasis on bio-safety and the complicated international relations have prompted domestic pharmaceutical companies to demand higher capabilities for the supply of core consumables for production. Considering the safety of supply chains and the stability of raw material supplies, pharmaceutical clients have a strong demand for seeking more cost-effective domestic chromatography suppliers. China's chromatography Industry has welcomed a huge trend and opportunity for domestic substitution, and domestic chromatography manufacturers represented by the issuer have already possessed the capability to produce first-class chromatography products. It is expected that in the future, the competitive landscape dominated by foreign giants and imported products will gradually be broken, further promoting the increase of domestic substitution rate.

Saifen Technology's analytical chromatography products are mainly used for analysis and testing in drug R&D and quality inspection, having established good business cooperation relationships with global large pharmaceutical groups, biopharmaceutical companies, and Innovative Drugs enterprises, including Roche, Pfizer, Eli Lilly and Co, Gan & Lee Pharmaceuticals, Chindex, Qilu Pharmaceuticals, Regeneron, Moderna, etc., and maintaining long-term stable cooperation with international industry giants such as Agilent, Thermo Fisher, VWR, and Sigma-Aldrich.

The funds raised from this issuance will be invested in the following projects:

In terms of finance, in the fiscal years 2021, 2022, and 2023, Sai Fen Technology achieved revenues of approximately 0.155 billion yuan, 0.213 billion yuan, and 0.245 billion yuan respectively. The company's net income was approximately 21.6202 million yuan, 48.2024 million yuan, and 54.1539 million yuan.